Bioresorbable Polymers Market Outlook Sees Value Rising to US$1.1 Billion by 2031

The commercial outlook for bioresorbable medical materials is strengthening. The bioresorbable polymers market stood at US$560 million in 2025 and is projected to reach US$1.1 billion by 2031 as absorbable polymers gain importance across fixation, sutures, stents, regenerative medicine, tissue engineering, and controlled drug delivery applications.

Market Overview and Growth Outlook

The commercial outlook for bioresorbable medical materials is strengthening. The bioresorbable polymers market stood at US$560 million in 2025 and is projected to reach US$1.1 billion by 2031 as absorbable polymers gain importance across fixation, sutures, stents, regenerative medicine, tissue engineering, and controlled drug delivery applications.

The bioresorbable polymers market is expected to grow at a CAGR of 12% during 2025–2031. These polymers are engineered to physically break apart and be absorbed within the body while maintaining characteristics such as biocompatibility, controlled degradation, and mechanical strength during their intended application.

The bioresorbable polymers market outlook is being shaped by a broader medical focus on minimally invasive procedures and technologies that can reduce repeat interventions. When temporary devices can perform their function and subsequently degrade, they address an important requirement across several advanced medical applications highlighted in the market analysis.

Request a free sample report:

https://www.stratviewresearch.com/Request-Sample/bioresorbable-polymers-market#form

Market Segmentation Analysis

The market is segmented by Type into Polylactic acid (PLA), Polyglycolic Acid (PGA), Polylactic-co-glycolic acid (PLGA), and Polycaprolactone (PCL). PLA is the largest type segment, supported by widespread availability, cost-effectiveness, favorable mechanical characteristics, biocompatibility, and established use in orthopedic implants, fixation products, and sutures.

PCL is the fastest-growing Type segment because its biocompatibility, slow degradation, and mechanical strength make it suitable for tissue engineering, regenerative medicine, and longer-term implants. Its growth illustrates how different degradation characteristics can support distinct medical-device requirements within the broader bioresorbable polymer portfolio.

By Application, the market includes Orthopedic Devices and Drug Delivery. Orthopedic Devices form the dominant application segment, with bioresorbable materials used in screws, pins, plates, and fixation devices. These components provide temporary support and then degrade, reducing the need for secondary removal procedures in relevant orthopedic applications.

Drug Delivery is identified as the fastest-growing application because bioresorbable polymers enable controlled drug release, improved bioavailability, and avoidance of device removal. These characteristics expand the role of bioresorbable materials into advanced therapeutic systems and contribute an important additional source of market growth beyond established orthopedic demand.

Regional Market Insights

Asia-Pacific represents the fastest-growing regional market. Increasing healthcare spending, expanding medical tourism, and rapid adoption of advanced medical devices are the principal factors identified. The source also notes investment in modern hospitals, regulatory support, and innovative treatments across China, India, and Southeast Asian countries as contributors to rising demand.

Emerging Trends Shaping the Bioresorbable Polymers Market

Medical polymer manufacturers are refining material properties for application-specific requirements. High-purity PLA with enhanced mechanical strength and controlled degradation has been developed for sutures and implants, demonstrating the industry's focus on improving performance characteristics that determine suitability for regulated medical uses.

Production capacity is expanding in response to medical-grade demand. Evonik's 2024 capacity increase for RESOMER bioresorbable polymers and its new German plant were aimed at requirements in fixation, stents, and drug delivery systems. This directly links market growth with additional manufacturing infrastructure for specialized medical polymers.

Regenerative medicine is encouraging cross-technology collaboration. DSM Biomedical and Xilloc Medical combined biomaterials engineering with 3D printing in a partnership focused on bioresorbable scaffolds for tissue repair and bone healing. Such initiatives indicate how bioresorbable polymer development is intersecting with new fabrication approaches in identified medical applications.

Key Growth Drivers of the Market

1. Minimally invasive treatment focus: Increasing emphasis on minimally invasive procedures supports temporary absorbable materials that may reduce the need for additional interventions after treatment.
2. Tissue engineering expansion: Controlled degradation, biocompatibility, and mechanical strength make bioresorbable polymers relevant to developing tissue engineering applications.
3. Regenerative medicine activity: Bioresorbable scaffolds for tissue repair and bone healing extend material demand into regenerative medical applications.
4. Drug delivery adoption: Controlled release and improved bioavailability, combined with elimination of device removal, support wider use within advanced drug delivery systems.
5. Material-science progress: Improvements in polymer purity, degradation control, mechanical properties, and functionality support next-generation implants, sutures, scaffolds, and therapeutic delivery products.

Competitive Landscape

Top Companies in the Market

The market has more than 80 players and is characterized as moderately fragmented. According to the source, the Top Players in stated order are Corbion N.V.; Evonik Industries AG; DSM Biomedical; Poly-Med Inc; Ashland Global Holdings Inc.; KLS Martin Grou; Foster Corporation; Zeus Industrial Products Inc.; SEQENS SAS; Reva Medical LLC.

Competitive positioning involves price, service offerings, and regional presence. Market developments additionally include polymer introductions, manufacturing capacity expansion, partnerships, and acquisitions. These developments illustrate the range of strategic actions taking place as suppliers respond to medical-device demand and evolving application requirements.

Conclusion and Strategic Outlook

The bioresorbable polymers market is projected to rise from US$560 million in 2025 to US$1.1 billion in 2031, representing 12% CAGR. Its market outlook is supported by medical demand for polymers that provide temporary functionality while maintaining biocompatibility, controlled degradation, and suitable mechanical properties.

The growth trajectory combines mature and emerging areas. PLA holds the largest Type position, PCL is expanding fastest, Orthopedic Devices anchor application demand, and Drug Delivery has the fastest application growth. Asia-Pacific's rapid expansion and continued material development further reinforce the industry's strategic direction through the forecast period.

FAQs – Bioresorbable Polymers Market

1. What is the market size and 2031 forecast?

The bioresorbable polymers market was valued at US$560 million in 2025. It is forecast to reach approximately US$1.1 billion by 2031.

2. How fast is the bioresorbable polymers market growing?

The bioresorbable polymers market is forecast to grow at around 12% CAGR through 2031. The projected growth reflects increasing use across multiple medical-device and advanced therapeutic applications.

3. Which factors are creating new demand?

Minimally invasive procedures, tissue engineering, regenerative medicine, controlled drug delivery, and advancements in polymer science are key stated demand factors. These developments support greater use of polymers engineered for controlled absorption and temporary medical functionality.

4. What does the regional analysis show?

Asia-Pacific is the fastest-growing market for bioresorbable polymers. Healthcare investment, medical tourism, advanced medical-device adoption, hospital development, regulatory support, and innovative treatments are cited as major contributors.

5. What risks or competitive factors should be considered?

The source identifies a moderately fragmented market with more than 80 players and competition involving price, service offerings, and regional presence. For market outlook assessments, these factors should be considered alongside continuing product development, manufacturing investments, partnerships, and acquisitions.